ATAI insider trading
NasdaqGM HealthcareAtaiBeckley Inc.: insider trade history from SEC Form 4 filings.
About AtaiBeckley Inc.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.
Company website: www.ataibeckley.com
ATAI insider activity at a glance
FilingIQ tracks 80 insider transactions for ATAI in filings since Jun 24, 2021. The most recent transaction is dated Sep 11, 2026.
Across the full history, 30 open-market purchases
and 15 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ATAI insider trades is 46.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ATAI Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ATAI?
- FilingIQ tracks 80 Form 4 insider transactions for ATAI (AtaiBeckley Inc.), covering filings from Jun 24, 2021 onwards. 11 of those are dated within the last 90 days.
- Are ATAI insiders net buyers or net sellers?
- Across the full Form 4 history for ATAI, 30 transactions (38%) were open-market purchases and 15 (19%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ATAI insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ATAI in?
- AtaiBeckley Inc. (ATAI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.29B.
Methodology & sources
Every ATAI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.